PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

Peripheral immune-checkpoint blockade with mAbs to programmed cell death receptor-1 (PD-1) (either nivolumab or pembrolizumab) or PD-Ligand-1 (PD-L1) (atezolizumab, durvalumab, or avelumab) alone or in combination with doublet chemotherapy represents an expanding treatment strategy for metastatic non-small cell lung cancer (mNSCLC) patients. This strategy lays on the capability of these mAbs to rescue tumor-specific cytotoxic T lymphocytes (CTLs) inactivated throughout PD-1 binding to PD-L1/2 in the tumor sites. This inhibitory interactive pathway is a physiological mechanism of prevention against dangerous overreactions and autoimmunity in case of prolonged and/or repeated CTL response to the same antigen peptides. Therefore, we have carried out a retrospective bioinformatics analysis by single-cell flow cytometry to evaluate if PD-1/PD-L1-blocking mAbs modulate the expression of specific peripheral immune cell subsets, potentially correlated with autoimmunity triggering in 28 mNSCLC patients. We recorded a treatment-related decline in CD4+ T-cell and B-cell subsets and in the neutrophil-to-lymphocyte ratio coupled with an increase in natural killer T (NKT), CD8+PD1+ T cells, and eosinophils. Treatment-related increase in autoantibodies [mainly antinuclear antibodies (ANAs) and extractable nuclear antigen (ENA) antibodies] as well as the frequency of immune-related adverse events were associated with the deregulation of specific immune subpopulations (e.g., NKT cells). Correlative biological/clinical studies with deep immune monitoring are badly needed for a better characterization of the effects produced by PD-1/PD-L1 immune-checkpoint blockade.

[1]  Qian Zhang,et al.  Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis , 2021, Cancer Chemotherapy and Pharmacology.

[2]  P. Tassone,et al.  Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis , 2021, Life.

[3]  H. Goldschmidt,et al.  FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology , 2021, Blood advances.

[4]  Elisa Catafal-Tardos,et al.  Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells , 2021, Cancers.

[5]  S. Zappavigna,et al.  Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade , 2021, Frontiers in Oncology.

[6]  W. Jiao,et al.  First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress , 2020, Frontiers in Pharmacology.

[7]  P. Tassone,et al.  HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis , 2020, Cells.

[8]  P. Tassone,et al.  Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade , 2020, Journal for immunotherapy of cancer.

[9]  A. Dietz,et al.  Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. , 2020, Thyroid : official journal of the American Thyroid Association.

[10]  P. Tagliaferri,et al.  Could PD-1/PDL1 immune checkpoints be linked to HLA signature? , 2019, Immunotherapy.

[11]  B. Duysinx,et al.  Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels , 2019, Acta oncologica.

[12]  P. Tassone,et al.  Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. , 2019, Molecular and clinical oncology.

[13]  G. Eapen,et al.  Lung Cancer. , 2019, The Medical clinics of North America.

[14]  L. Xia,et al.  PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions , 2019, The oncologist.

[15]  M. Najafi,et al.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.

[16]  Yoon Dae Han,et al.  Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. , 2018, Cancer research.

[17]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.

[18]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[20]  C. Rudin,et al.  Atezolizumab for the treatment of non-small cell lung cancer , 2017, Expert review of clinical pharmacology.

[21]  I. Preeshagul,et al.  New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab , 2017, Lung Cancer.

[22]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[23]  Ignacio I Wistuba,et al.  Lung Cancer Biomarkers. , 2017, Hematology/oncology clinics of North America.

[24]  P. Tassone,et al.  Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients , 2016, Cell Death Discovery.

[25]  P. Tassone,et al.  The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response , 2016, Cell Death and Disease.

[26]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[27]  P. Tassone,et al.  Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial , 2014, Journal of immunotherapy.

[28]  A. Rossi,et al.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients , 2013, Cancer biology & therapy.

[29]  A. Fioravanti,et al.  Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen , 2012, Journal of chemotherapy.

[30]  P. Tassone,et al.  Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) , 2008, Clinical Cancer Research.

[31]  C. Miracco,et al.  Occurrence of Autoimmunity in a Long-Term Survivor with Metastatic Colon Carcinoma Treated with a New Chemo-Immunotherapy Regimen , 2008, Journal of chemotherapy.

[32]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[33]  Robert C. Wolpert,et al.  A Review of the , 1985 .